18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors

Yaojun Zhang, Adam E. Frampton, Jack L. Martin, Charis Kyriakides, Jan Jin Bong, Nagy A. Habib, Panagiotis Vlavianos, Long R. Jiao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: To evaluate the effectiveness of PET in differentiating malignant from benign pancreatic cystic tumors. Methods: Between 2009 and 2010, all patients with pancreatic cystic tumors who had PET, triple phase contrast computed tomography (CT) and endoscopic ultrasound (EUS) were reviewed. Clinicopathological characteristics and final histology were correlated with preoperative PET, CT and EUS to assess the value of each modality in detecting malignant from benign lesions for clinical decision-making. Results: Twenty of a total of 116 patients with pancreatic cystic tumors had 18F-FDG PET because of diagnostic difficulties after evaluation with conventional modalities. Sensitivity and specificity of PET in differentiating malignant from benign pancreatic cystic tumors were 100% and 93.75%, with an accuracy of 95%. PET had the best sensitivity, specificity and accuracy for detecting malignant cystic tumors compared with CT and EUS. In 5 cases, the PET results altered the treatment options completely to follow-up instead of surgery (n= 2), limited resection instead of Whipple's resection (n= 1), and surgery instead of follow-up (n= 2). Conclusions: PET is an accurate, non-invasive method to distinguish malignant from benign pancreatic cystic tumors and can be used as an adjunct to facilitate clinical decision making.

Original languageEnglish
Pages (from-to)982-985
Number of pages4
JournalNuclear Medicine and Biology
Volume39
Issue number7
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Neoplasms
Tomography
Sensitivity and Specificity
Histology

Keywords

  • Computed tomography
  • Diagnosis
  • Endoscopic ultrasound
  • Pancreatic cystic tumors
  • Positron emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Zhang, Y., Frampton, A. E., Martin, J. L., Kyriakides, C., Bong, J. J., Habib, N. A., ... Jiao, L. R. (2012). 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. Nuclear Medicine and Biology, 39(7), 982-985. https://doi.org/10.1016/j.nucmedbio.2012.03.005

18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. / Zhang, Yaojun; Frampton, Adam E.; Martin, Jack L.; Kyriakides, Charis; Bong, Jan Jin; Habib, Nagy A.; Vlavianos, Panagiotis; Jiao, Long R.

In: Nuclear Medicine and Biology, Vol. 39, No. 7, 10.2012, p. 982-985.

Research output: Contribution to journalArticle

Zhang, Y, Frampton, AE, Martin, JL, Kyriakides, C, Bong, JJ, Habib, NA, Vlavianos, P & Jiao, LR 2012, '18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors', Nuclear Medicine and Biology, vol. 39, no. 7, pp. 982-985. https://doi.org/10.1016/j.nucmedbio.2012.03.005
Zhang, Yaojun ; Frampton, Adam E. ; Martin, Jack L. ; Kyriakides, Charis ; Bong, Jan Jin ; Habib, Nagy A. ; Vlavianos, Panagiotis ; Jiao, Long R. / 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. In: Nuclear Medicine and Biology. 2012 ; Vol. 39, No. 7. pp. 982-985.
@article{7be208da84624838a28e1834387e775e,
title = "18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors",
abstract = "Objectives: To evaluate the effectiveness of PET in differentiating malignant from benign pancreatic cystic tumors. Methods: Between 2009 and 2010, all patients with pancreatic cystic tumors who had PET, triple phase contrast computed tomography (CT) and endoscopic ultrasound (EUS) were reviewed. Clinicopathological characteristics and final histology were correlated with preoperative PET, CT and EUS to assess the value of each modality in detecting malignant from benign lesions for clinical decision-making. Results: Twenty of a total of 116 patients with pancreatic cystic tumors had 18F-FDG PET because of diagnostic difficulties after evaluation with conventional modalities. Sensitivity and specificity of PET in differentiating malignant from benign pancreatic cystic tumors were 100{\%} and 93.75{\%}, with an accuracy of 95{\%}. PET had the best sensitivity, specificity and accuracy for detecting malignant cystic tumors compared with CT and EUS. In 5 cases, the PET results altered the treatment options completely to follow-up instead of surgery (n= 2), limited resection instead of Whipple's resection (n= 1), and surgery instead of follow-up (n= 2). Conclusions: PET is an accurate, non-invasive method to distinguish malignant from benign pancreatic cystic tumors and can be used as an adjunct to facilitate clinical decision making.",
keywords = "Computed tomography, Diagnosis, Endoscopic ultrasound, Pancreatic cystic tumors, Positron emission tomography",
author = "Yaojun Zhang and Frampton, {Adam E.} and Martin, {Jack L.} and Charis Kyriakides and Bong, {Jan Jin} and Habib, {Nagy A.} and Panagiotis Vlavianos and Jiao, {Long R.}",
year = "2012",
month = "10",
doi = "10.1016/j.nucmedbio.2012.03.005",
language = "English",
volume = "39",
pages = "982--985",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors

AU - Zhang, Yaojun

AU - Frampton, Adam E.

AU - Martin, Jack L.

AU - Kyriakides, Charis

AU - Bong, Jan Jin

AU - Habib, Nagy A.

AU - Vlavianos, Panagiotis

AU - Jiao, Long R.

PY - 2012/10

Y1 - 2012/10

N2 - Objectives: To evaluate the effectiveness of PET in differentiating malignant from benign pancreatic cystic tumors. Methods: Between 2009 and 2010, all patients with pancreatic cystic tumors who had PET, triple phase contrast computed tomography (CT) and endoscopic ultrasound (EUS) were reviewed. Clinicopathological characteristics and final histology were correlated with preoperative PET, CT and EUS to assess the value of each modality in detecting malignant from benign lesions for clinical decision-making. Results: Twenty of a total of 116 patients with pancreatic cystic tumors had 18F-FDG PET because of diagnostic difficulties after evaluation with conventional modalities. Sensitivity and specificity of PET in differentiating malignant from benign pancreatic cystic tumors were 100% and 93.75%, with an accuracy of 95%. PET had the best sensitivity, specificity and accuracy for detecting malignant cystic tumors compared with CT and EUS. In 5 cases, the PET results altered the treatment options completely to follow-up instead of surgery (n= 2), limited resection instead of Whipple's resection (n= 1), and surgery instead of follow-up (n= 2). Conclusions: PET is an accurate, non-invasive method to distinguish malignant from benign pancreatic cystic tumors and can be used as an adjunct to facilitate clinical decision making.

AB - Objectives: To evaluate the effectiveness of PET in differentiating malignant from benign pancreatic cystic tumors. Methods: Between 2009 and 2010, all patients with pancreatic cystic tumors who had PET, triple phase contrast computed tomography (CT) and endoscopic ultrasound (EUS) were reviewed. Clinicopathological characteristics and final histology were correlated with preoperative PET, CT and EUS to assess the value of each modality in detecting malignant from benign lesions for clinical decision-making. Results: Twenty of a total of 116 patients with pancreatic cystic tumors had 18F-FDG PET because of diagnostic difficulties after evaluation with conventional modalities. Sensitivity and specificity of PET in differentiating malignant from benign pancreatic cystic tumors were 100% and 93.75%, with an accuracy of 95%. PET had the best sensitivity, specificity and accuracy for detecting malignant cystic tumors compared with CT and EUS. In 5 cases, the PET results altered the treatment options completely to follow-up instead of surgery (n= 2), limited resection instead of Whipple's resection (n= 1), and surgery instead of follow-up (n= 2). Conclusions: PET is an accurate, non-invasive method to distinguish malignant from benign pancreatic cystic tumors and can be used as an adjunct to facilitate clinical decision making.

KW - Computed tomography

KW - Diagnosis

KW - Endoscopic ultrasound

KW - Pancreatic cystic tumors

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84866025832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866025832&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2012.03.005

DO - 10.1016/j.nucmedbio.2012.03.005

M3 - Article

C2 - 22560970

AN - SCOPUS:84866025832

VL - 39

SP - 982

EP - 985

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 7

ER -